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1\. Is there any evidence that haemophilia patients in the UK have been infected with variant Creutzfeldt--Jakob disease (vCJD) via therapies made from contaminated blood donations? Phrased differently, are there good data to support the decision in the UK to phase out the use of recombinant factor VIII (rFVIII) therapies processed with plasma additives, and are the surgical precautions in treating haemophilia patients necessary?

DOLAN: Initial discussions surrounding these issues were definitely controversial, and we in the medical community were not sure how far we needed to go in trying to protect patients. But the recommendations and surgical measures were devised after very detailed consultation with experts who knew far more about prion disease than we did.

Certain decisions, such as ceasing use of UK plasma‐derived therapies, were difficult for both patients and their providers. But the subsequent events, in particular the later evidence that there have been at least two probable cases of transfusion‐transmitted variant CJD, seem to justify that early stance by not just the UK but other countries as well.

2\. Do you think that the fact that vCJD has not been identified in any patient receiving plasma derivatives worldwide since 1980 suggests that the risk of vCJD is minimal or non‐existent from these therapies?

IRONSIDE: First of all, let\'s be quite clear about why 1980 has become a benchmark. The date 1980 was chosen simply because that was thought to be the earliest date at which human exposure to bovine spongiform encephalopathy (BSE) in the UK was likely to have occurred. Overall, human exposure to BSE probably would be very low in the early 1980s and highest in the late 1980s and early 1990s. It is also important to remember that we are dealing with a primary disease transmission with an incubation period of approximately 15 years on average. So, we may have to wait a few more years before we can be certain about the absolute risk of contracting vCJD.

I would be very cautious about relaxing policies and guidelines at present because, as we all understand, there are other emerging infectious agents -- identified and unidentified -- that are cause for concern in addition to the vCJD‐causing prion.

3\. Do you know of any vCJD transmissions by plasma‐derived FVIII/FIX therapies?

IRONSIDE: At present, no. There is no evidence that vCJD has occurred or infection has been transmitted by these therapies. Although, as I stated earlier, this may be due to the fact that we are dealing with an agent that has a long incubation period. The level of infectivity in plasma therapies may be lower or variable. But it is too soon to exclude that possibility.

The United Kingdom Haemophilia Centre Doctors' Organisation, along with several patient groups, is engaged in enhanced surveillance of the haemophilia population. We are looking for evidence of vCJD -- even of subclinical infection -- in patients who died or who have a lymphoid tissue biopsy for whatever reason.

4\. What is the likely impact of the UK experience with vCJD in the United States and what might those treatment implications be?

DOLAN: Reported cases of BSE in the United States are very few. And if the number of cases remains at this low level, or even disappears altogether, then perhaps US practitioners and policy makers won\'t be obligated to take the more sweeping measures that we did in the UK. However, as a general concept, we must all remember that emerging pathogens can affect transfusion therapy. So, based on the UK experience, if healthcare providers have an opportunity to minimize risk to patients, then it is a prudent course of direction that should be considered seriously and likely taken.

5\. Are there data that leukodepletion of blood will decrease the risk of transmitting vCJD? If not, what is the rationale?

IRONSIDE: This is a very interesting question because the UK has been using leukodepletion as one of its main strategies for risk reduction in terms of blood transfusion. The data from experimental studies do indicate that although leukodepletion will reduce infectivity, it will not remove it entirely.

Because leukodepletion does not remove all infectivity, there have been a number of other approaches that utilize additional filters that might bind more specifically to any free prion protein in the plasma and thus, further reduce the risk.

6\. Please describe the results of experiments in which blood was spiked with vCJD concentrate to determine whether prions could be removed.

IRONSIDE: Results of a spiking experiment were published using blood containing a range of prions, including both sporadic and variant CJD prions. The study looked at the effect of plasma fractionation in removing the prions. And indeed, fractionation did seem to have a positive effect.

However, there are a number of concerns about these spiking experiments because they involve inoculating brain homogenate into blood and using that as the spike. Essentially, it is infected brain tissue, which is very unphysiological. Therefore, it is unlikely to replicate the form of infectivity found in blood‐endogenous infection, where it is probably free in plasma and not aggregated as it would be in brain. So, while the spiking experiments do provide some reassuring information, a number of questions persist as to just how valid the spiking method is.

7\. What about the results of the study in which 11% of patients who received recombinant therapy only were seropositive for parvovirus B19 antibodies soon after start of treatment? Aren\'t recombinant therapies totally free of any virus transmission risk?

TAPPER: As has been stated, the non‐lipid‐encased viruses are obviously much more difficult to inactivate. So if you ask, do the current techno‐logies inactivate all pathogens, the answer is clearly no, they do not.

Parvovirus is one of the classic markers for these types of viruses. In children, parvovirus is relatively benign, but older people tend to get sick from it. Parvovirus can be viewed as a marker for pathogens that are either difficult to inactivate or that simply have not been fully described as yet. There are many viruses that fall into this latter category. For example, where did severe acute respiratory syndrome come from? Where did the coronavirus come from? It is clearly a novel virus that probably made a cross‐species jump. You could say very much the same thing about human immunodeficiency virus when it was first described in industrialized countries in the 1980s, but clearly, phylogenetically, it had been present in Africa for at least 50 years prior to that time.

Factors such as the vastly increased ability of populations to travel, the issues surrounding land encroachment and the disruptions of the natural barriers between humans and humans and between humans and animals are clearly going to continue. And within that context, you can anticipate that new pathogens will continue to emerge, at least some of which, like West Nile virus, will be transmissible via blood.

PIPE: The medical community is not particularly concerned with parvovirus, but we\'re looking at it as a marker because it is one of the non‐lipid‐enveloped viruses for which we can actually screen. At this point in time, the theoretical concern would involve early seroconversions among patients who have depended solely on recombinant therapies. We would need to ask: is there the potential for another infectious agent -- which either has or has not emerged yet, or that we don\'t have a test for -- to become a threat to these patients?

What it comes down to is an issue of vigilance, and I think it is encouraging to see that when testing is available, such as prion screening, we are actively looking for patients who have the protein. Another encouraging example involves West Nile virus. It was only a very short period of time from its appearance to actually having an effective screening tool; this rapid response illustrates that the scientific world can respond quickly to address these kinds of issues.

8\. What is the justification of continuing to use a therapy that is processed with bovine plasma protein?

PIPE: In a single clinic, I might talk to a patient with von Willebrand disease and a patient with another rare coagulation deficiency, both of whom would rely on plasma derivatives. With these patients I discuss the continued vigilance and screening that have resulted in the safety of these therapies thus far. I think it is important to inform them that there are ongoing concerns with respect to emerging pathogens, but also that as we learn more about potentially infective agents, we establish policies that will go a long way toward preventing another crisis in which emerging pathogens contaminate blood‐derived therapies.

Alternatively, I will have a conversation with a family member or patient with either haemophilia A or haemophilia B and discuss with them the availability of newer therapies that are not processed with human or animal protein additives. The conversation with the patient with von Willebrand disease is very different than the one with the haemophilia patient: one is a conversation of reassurance, and the other a conversation of striving to be proactive, to help these patients and their caregivers consider new therapies that may reduce the risk of infection with disease‐causing agents.

Our history with haemophilia patients is interesting. In 1992, we switched all of our paediatric patients on FVIII to recombinant therapies. Then, in 1998 when recombinant FIX was available, we switched all of our patients from plasma‐derived FIX to recombinant. That therapy had reduced recovery time in paediatric patients, and as a result, many patients had to use up to twice the amount of factor units that they would have had they remained on plasma‐derived therapies. There is also the increased cost associated with the therapy.

The decision to switch patients to recombinant therapies was not based on any evidence of a known infectious agent being transmitted by plasma derivatives. Yet if you look at the data from the US Centers for Disease Control and Prevention on the adoption of recombinant therapies in paediatric patients, and indeed for adult patients around the US, it is quite remarkable how enthusiastically patients and clinicians have embraced recombinant technology.

For some patients, unfortunately, choice is not an option. There are patients in some areas of the US who do not even have access to recombinants. So, for these patients we must rely on the 20 years of safety that we have enjoyed with plasma derivatives. This relative safety should not lull us into a mode of complacency where we ignore emerging pathogens such as vCJD.
